Commercialization of cavitation-enhancing nanodroplets for DNA sample fragmentation in NGS applications

用于 NGS 应用中 DNA 样品碎片化的空化增强纳米液滴的商业化

基本信息

批准号：
10081304
负责人：
Sandeep Kasoji
金额：
$ 84.47万
依托单位：
TRIANGLE BIOTECHNOLOGY, INC.
依托单位国家：
美国
项目类别：
财政年份：
2018
资助国家：
美国
起止时间：
2018-07-05 至 2022-08-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10081304
关键词：
Acoustics Address Base Pairing Bathing Biological Biotechnology Cell Line DNA DNA Fragmentation DNA Sequencing Facility Development Digestion Due Process Enhancement Technology Equipment Exclusion Exposure to Face Fluorocarbons Freezing Generations Genes Genetic Genomic DNA Genomics Gold Head Health Technology Human Genome Project Individual Industry Industry Standard Interview Large-Scale Sequencing Legal patent Length Libraries Methods Modification Output Pain Performance Phase Positioning Attribute Pregnancy Tests Preparation Price Production Protocols documentation Public Health Quality Control Reagent Reproducibility Risk Sales Sampling Ships Signal Transduction Single Nucleotide Polymorphism Small Business Innovation Research Grant Sonication Standardization Technology Testing Time Transistors Tube Ultrasonics Validation Work commercialization cost design exome gene therapy genetic analysis genetic testing human DNA improved innovation insertion/deletion mutation instrument nanoDroplet next generation sequencing novel personalized diagnostics precision medicine product development prototype research and development scale up success validation studies whole genome

项目摘要

PROJECT SUMMARY The completion of the Human Genome Project has established NGS as the gold standard technology for personalized/precision medicine and diagnostics. Genetic testing kits are now as readily available as pregnancy test kits, and advances in genetic analysis, gene therapy, and genetic modification in the 21st century promise to parallel the development of transistors and integrated circuits in the 20th century. The challenge is that technology for preparing biological samples for sequencing has not maintained a similar rapid advancement to gene sequencing. Fragmentation of DNA randomly without bias is an essential, but difficult step in the preparation of genomic DNA for NGS applications. A narrow range of DNA fragment lengths is required for sequencing, and inefficient or inconsistent fragmentation will result in incomplete or excluded reads, corrupting the sequencing. Sonication, which fragments DNA through cavitation, is the gold standard for DNA fragmentation. However, our customer discover interviews have reinforced that this is a significant pain point in their sample preparation process due to its low throughput and inconsistency, particularly for industry developing large-scale sequencing efforts. We have invented a novel nanodroplet reagent that enhances cavitation from an acoustic sonicator, and greatly improves consistency and reduces time and acoustic power requirements for DNA fragmentation. Triangle Biotechnology has licensed the patents describing this cavitation enhancing technology. We have achieved milestones proposed in Phase I, demonstrating product and technical feasibility. With this SBIR Phase II, we will perform key R&D tasks, product development, and validation studies to prepare for commercialization. Success of this project will enable a novel commercial solution for addressing market pain points: substantially improving throughput and consistency of DNA fragmentation for NGS sample preparation while reducing cost.

项目摘要人类基因组项目的完成已确立了NGS作为黄金标准技术个性化/精度医学和诊断。基因测试套件现在与怀孕一样容易获得测试套件，以及21世纪的遗传分析，基因疗法和遗传修饰的进步有望与20世纪晶体管和综合电路的发展相似。挑战是技术用于准备测序的生物样品并未保持与基因相似的快速发展测序。随机无偏见的DNA分裂是制备过程中必不可少但困难的一步 NGS应用的基因组DNA。测序需要狭窄的DNA片段长度，并且需要效率低下或不一致的分裂将导致不完整或排除的读取，从而破坏测序。超声处理是通过空化来碎片DNA的，是DNA碎片化的金标准。但是，我们的客户发现访谈加强了这是他们样本中的重要痛苦点由于其吞吐量低和不一致而导致的准备过程，特别是对于开发大规模的行业测序工作。我们发明了一种新型的纳米型试剂，可增强声音超声器的气蚀，并极大地提高了一致性，并减少了DNA碎片的时间和声音能力要求。 Triangle生物技术已获得了描述这种空化增强技术的专利。我们已经实现了第一阶段提出的里程碑，证明了产品和技术可行性。和在第二阶段，我们将执行关键的研发任务，产品开发和验证研究以准备商业化。该项目的成功将为解决市场提供新的商业解决方案疼痛点：NGS样品的DNA碎片的吞吐量和一致性大大提高降低成本的准备工作。